CFO Davis Jason buys 70,000 shares at $0.41; company unprofitable ($-5.8M net income); cluster pattern with 2 other insiders buying within 14 days.
CFO Jason Davis purchased 70,000 shares at $0.41 on 2026-03-02, with this representing his initial holdings position in FibroBiologics. The transaction occurs at a significant discount to the 52-week high of $27.60, representing a -71.8% gap from peak levels. Most notably, this purchase is part of a cluster pattern: 2 other insiders also bought within the past 14 days, suggesting coordinated accumulation by the leadership team. However, the company's fundamentals remain challenged—it reported a net loss of $-5.8M over its most recent full fiscal year. While the stock has rebounded +52.6% over 90 days and +17.2% over 30 days, the cluster buying by multiple executives during unprofitable operations warrants investor scrutiny to understand whether leadership sees inflection potential or if other material developments are driving the acquisitions.